ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient outcomes"

  • Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting

    Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment

    Daniel E. Furst1, Emma Sullivan2, James Pike3, James Piercy4, Jacqueline Palmer5 and Vivian Herrera5, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Adelphi Real World, Manchester, United Kingdom, 3Statistics, Adelphi Real World, Macclesfield, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
  • Abstract Number: 1746 • 2015 ACR/ARHP Annual Meeting

    Patient’s Ability of Coping Is Influencing the Correlation Between Clinical and Ultrasonographic Evidence of Disease Activity in Psoriatic Arthritis

    Brigitte Michelsen1, Andreas P Diamantopoulos1,2, Hilde Berner Hammer3, Dag Magnar Soldal4, Arthur Kavanaugh5 and Glenn Haugeberg1,6,7, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, 5University of California, San Diego School of Medicine, LaJolla, CA, 6Rheumatology, Martina Hansens Hospital, Gjettum, Norway, 7Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway

    Background/Purpose: Coping may be defined as the set of adaptive processes a patient uses to live well with aspects of disease such as pain. Coping…
  • Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting

    Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?

    Joanna Robson1, Karolina Lada2, Anne Miller3, Wilby Williamson1, Julia Newton2 and Raashid Luqmani4, 1Rheumatology, University of Oxford, Oxford, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, 4Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
  • Abstract Number: 2327 • 2015 ACR/ARHP Annual Meeting

    Documentation of Clinical Improvement in Patient with Polymyalgia Rheumatica According to MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data): Longitudinal Analysis from Routine Care

    Isabel Castrejón1, Annie Huang1, Sarah L. Everakes2, Ailda Nika1, Winston Sequeira1 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL

    Background/Purpose: RAPID3 is an index found on the MDHAQ, which is effective in rheumatoid arthritis (RA) clinical trials and clinical care (1). MDHAQ/RAPID3 also is…
  • Abstract Number: 2493 • 2015 ACR/ARHP Annual Meeting

    Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care

    Pedro Ivan Santos-Moreno1, Ginna Saavedra2, Rosana Ramirez2, Laura Villarreal2, Ana Bolena Cardozo2, Vanessa Giraldo2, Paola Martinez2, Adriana Sanchez2, Merle Sanchez2, Danny Gomez2 and Juan Manuel Bello2, 1Rheumatology, Biomab, Center for Rheumatoid Arthritis., Bogota, Colombia, 2Rheumatology, Biomab, Center for Rheumatoid Arthritis, Bogota, Colombia, Bogota, Colombia

    Background/Purpose: Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA). Moreover,…
  • Abstract Number: 2640 • 2015 ACR/ARHP Annual Meeting

    Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options

    Peter C. Taylor1, Emma Sullivan2, Robert Wood3, James Piercy3, Rieke Alten4, Juan J Gomez-Reino5, Philippe Bertin6, Roberto Caporali7, Radu Vasilescu8, Dean Spurden9 and Jose Alvir10, 1Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, 2Adelphi Real World, Manchester, United Kingdom, 3Adelphi Real World, Macclesfield, United Kingdom, 4Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 5Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, 6Rheumatology, CHU Dupuytren, Limoges, France, 7University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 8Medical Affairs, Pfizer Inc, Brussels, Belgium, 9Pfizer Inc, Tadworth, United Kingdom, 10Global Health and Value, Pfizer Inc, New York, NY

    Background/Purpose: Current recommendations for pharmacologic management of rheumatoid arthritis (RA) advise dose titration or switching treatment if goals of remission or low disease activity are…
  • Abstract Number: 2641 • 2015 ACR/ARHP Annual Meeting

    Correlation of Rheumatologists’ Perceptions of RA Severity with Observed Disease Activity, Patient Impact and Treatment Patterns

    Peter C. Taylor1, Juan J Gomez-Reino2, Roberto Caporali3, Rieke Alten4, Philippe Bertin5, Emma Sullivan6, Robert Wood7, James Piercy7, Radu Vasilescu8, Dean Spurden9 and Jose Alvir10, 1Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, 2Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, 3University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 4Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 5Rheumatology, CHU Dupuytren, Limoges, France, 6Adelphi Real World, Manchester, United Kingdom, 7Adelphi Real World, Macclesfield, United Kingdom, 8Medical Affairs, Pfizer Inc, Brussels, Belgium, 9Pfizer Inc, Tadworth, United Kingdom, 10Global Health and Value, Pfizer Inc, New York, NY

    Background/Purpose: Efforts have been made in recent years to standardize the clinical assessment of RA patients with increased focus on objective measures, such as the…
  • Abstract Number: 2667 • 2015 ACR/ARHP Annual Meeting

    Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment

    Peter C. Taylor1, Rieke Alten2, Philippe Bertin3, Roberto Caporali4, Juan J Gomez-Reino5, Emma Sullivan6, Robert Wood7, James Piercy7, Radu Vasilescu8, Dean Spurden9 and Jose Alvir10, 1Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, 2Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3Rheumatology, CHU Dupuytren, Limoges, France, 4University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 5Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, 6Adelphi Real World, Manchester, United Kingdom, 7Adelphi Real World, Macclesfield, United Kingdom, 8Medical Affairs, Pfizer Inc, Brussels, Belgium, 9Pfizer Inc, Tadworth, United Kingdom, 10Global Health and Value, Pfizer Inc, New York, NY

    Background/Purpose: Despite an increasing armamentarium of efficacious treatments for Rheumatoid Arthritis (RA), sustained remission remains an unrealistic expectation for many patients, with most experiencing ongoing…
  • Abstract Number: 2672 • 2015 ACR/ARHP Annual Meeting

    Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States

    George A. Karpouzas1, Taylor Draper2, Elizabeth Hernandez1 and Sarah Ormseth1, 1Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Psychology, Loma Linda University, Loma Linda, CA

    Background/Purpose: Patients and physicians often differ in their perceptions of disease activity in Rheumatoid arthritis (RA) as described by patients' and evaluators' global assessments (PGA…
  • Abstract Number: 2686 • 2015 ACR/ARHP Annual Meeting

    No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission

    Myrthe van der Ven1, T. Martijn Kuijper1, Andreas Gerards2, I. Tchetverikov3, A.E.a.M. Weel1,4, Derkjen van Zeben5, Mieke Hazes1 and J.J. Luime1, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 3Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, 4Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 5Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands

    Background/Purpose: Several studies assessed disease activity with ultrasound in rheumatoid arthritis (RA) patients who were in clinical remission. These studies found ultrasound synovitis in 48-73%…
  • Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting

    Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study

    Filip van Den Bosch1,2, Edit Drescher3, Jan Rosa4, Ronald Pedersen5, Randi Bonin6, Bonnie Vlahos7, Jack F Bukowski6 and Sameer Kotak8, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Csolnoky Ferenc Hospital, Veszprém, Hungary, 4Mediscan Group, Prague, Czech Republic, 5Department of Biostatistics, Pfizer, Collegeville, PA, 6Clinical Affairs, Pfizer, Collegeville, PA, 7GIPB - Clinical Sciences, Pfizer, Collegeville, PA, 8Global Health and Value, Pfizer, New York, NY

    Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…
  • Abstract Number: 2721 • 2014 ACR/ARHP Annual Meeting

    Patients’ Perspective of Skin Involvement in Systemic Sclerosis

    Ada Man1, Amy Wu1, Jessica Ziemek2, Romy Christmann1, Robert W. Simms1, David T. Felson3 and Robert Lafyatis4, 1Rheumatology, Boston University School of Medicine, Boston, MA, 2Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4Arthritis Center, Boston University, Boston, MA

    Background/Purpose:   Skin tightness and other abnormalities of the skin are the hallmark features of systemic sclerosis (SSc).  While skin involvement may significantly impact a…
  • Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting

    Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes

    Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom

    Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
  • Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting

    Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity

    Francesca Ometto1, Costantino Botsios2, Livio Bernardi1, Bernd Raffeiner2,3, Leonardo Punzi4 and Andrea Doria4, 1Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, 2Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 3Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, 4Department of Medicine - DIMED, University of Padova, Padova, Italy

    Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
  • Abstract Number: 2318 • 2014 ACR/ARHP Annual Meeting

    Increasing Rates of Remission in Juvenile Idiopathic Arthritis through a Quality Improvement Learning Network – the Pediatric Rheumatology Care and Outcomes Improvement Network

    Esi M. Morgan DeWitt1, Stacy P. Ardoin2, C. April Bingham3, Beth S. Gottlieb4, Ronald Laxer5, Nancy Griffin6, Jesse Pratt7, Anne Paul8, Daniel Lovell9, Judyann C. Olson10, Murray H. Passo11, Jennifer E. Weiss12, Tzielan C. Lee13, Sheetal S. Vora14, Melissa M. Hazen15 and Peter Margolis16, 1Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 3Penn State Hershey Children's Hospital, Hershey, PA, 4Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 5Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 6James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 10Medical College of Wisconsin, Milwaukee, WI, 11Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 12Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 13Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, 14University of North Carolina Chapel Hill, Chapel Hill, NC, 15Division of Immunology, Boston Children's Hospital, Boston, MA, 16Clinical Effectiveness, Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) since 2011 has used quality improvement (QI) methods, chronic illness care model interventions, and a…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology